

MATERIAL DATA SHEET**p53, human recombinant****Cat. # SP-454**

p53 is well known for its key role as a tumor suppressor protein. It is 393 amino acids (aa) in length with a predicted molecular weight of 44 kDa. It belongs to the p53 family that also includes p63 and p73 (1,2). Structurally, p53 is characterized by an N-terminal transactivation domain, central DNA-binding and oligomerization domains, and a C-terminal regulatory domain. It is thought to exist as a homotetramer, and it exhibits approximately 72% and 76% aa identity with its mouse and rat orthologs, respectively. Mutations in the p53 gene are one of the most frequent genomic events accompanying oncogenic transformation (3). p53 responds to signals such as DNA damage or cell stress primarily through its actions as a transcription factor. Among its gene targets are a range of factors that promote DNA repair mechanisms or apoptosis, including cell cycle regulatory proteins and members of the Bcl-2 family (3). Because of its critical role in genomic homeostasis, p53 activities are tightly regulated by a network of protein-protein interactions, microRNAs, and a range of post-translational modifications, including phosphorylation, acetylation, methylation, and ubiquitination (3-5). A widely studied regulator is Murine Double Minute 2 (MDM2). MDM2 is known to suppress p53 activity through direct binding or through its actions as a Ubiquitin ligase (E3) that catalyzes p53 ubiquitination and proteasome-mediated degradation (6,7). This recombinant protein is untagged.

Product Information

Quantity:	20 µg
Stock:	X mg/ml (X µM) in 50 mM HEPES pH 7.5, 450 mM NaCl, 10% glycerol, 30 µM ZnCl ₂ . Actual concentration varies with lot number.
MW:	44 kDa
Purity:	> 80% by SDS-PAGE

Use & Storage

Use:	Recombinant Human p53 is ideal for use as a control substrate for <i>in vitro</i> Ubiquitin conjugation. Reaction conditions will need to be optimized for each specific application. We recommend an initial Recombinant Human p53 concentration of 0.1-2.5 µM.
Storage:	Store at -80°C. Avoid multiple freeze/thaw cycles.

Literature

- References:**
1. Arrowsmith, C.H. *et al.* (1999) *Cell Death Differ.* **6**:1169.
 2. Dötsch, V. *et al.* (2010) *Cold Spring Harb. Perspect. Biol.* **2**:a004887.
 3. Freed-Pastor, W.A. & C. Prives (2012) *Genes Dev.* **26**:1268.
 4. Feng, Z. *et al.* (2011) *J. Mol. Cell Biol.* **3**:44.
 5. Gu, B. & W.-G. Zhu (2012) *Int. J. Biol. Sci.* **8**:672.
 6. Momand, J. *et al.* (1992) *Cell* **69**:1237.
 7. Haupt, Y. *et al.* (1997) *Nature* **387**:296.

For Laboratory Research Use Only, Not For Use in Humans

Rev: 03/22/2013

840 Memorial Drive, Cambridge, MA 02139 Phone: 617-576-2210 FAX: 617-492-3565

www.bostonbiochem.com

The contents of this datasheet (unless otherwise noted) are Copyright © 2008 Boston Biochem, Inc. All rights reserved. Duplication in whole or in part is strictly prohibited without the express written consent of Boston Biochem, Inc. "Boston Biochem" is a Trademark of Boston Biochem, Inc., 840 Memorial Drive, Cambridge, MA 02139.